PMC:7408073 / 16535-16928 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T105","span":{"begin":65,"end":80},"obj":"Body_part"},{"id":"T106","span":{"begin":232,"end":242},"obj":"Body_part"},{"id":"T107","span":{"begin":382,"end":387},"obj":"Body_part"}],"attributes":[{"id":"A105","pred":"fma_id","subj":"T105","obj":"http://purl.org/sig/ont/fma/fma49893"},{"id":"A106","pred":"fma_id","subj":"T106","obj":"http://purl.org/sig/ont/fma/fma9462"},{"id":"A107","pred":"fma_id","subj":"T107","obj":"http://purl.org/sig/ont/fma/fma7088"}],"text":"Interestingly, in a rat model of myocardial infarction following coronary artery ligation, there is evidence that C16/MLN-4760 (a specific ACE2 inhibitor, see later) administration inhibits fibrosis and hypertrophy of non-infarcted myocardium and increases diastolic relaxation, raising the possibility that ACE2 activity may have some adverse effects on post-myocardial infarction heart [52]."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T30","span":{"begin":65,"end":80},"obj":"Body_part"},{"id":"T31","span":{"begin":74,"end":80},"obj":"Body_part"},{"id":"T32","span":{"begin":232,"end":242},"obj":"Body_part"},{"id":"T33","span":{"begin":382,"end":387},"obj":"Body_part"}],"attributes":[{"id":"A30","pred":"uberon_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/UBERON_0001621"},{"id":"A31","pred":"uberon_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/UBERON_0001637"},{"id":"A32","pred":"uberon_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/UBERON_0002349"},{"id":"A33","pred":"uberon_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/UBERON_0000948"}],"text":"Interestingly, in a rat model of myocardial infarction following coronary artery ligation, there is evidence that C16/MLN-4760 (a specific ACE2 inhibitor, see later) administration inhibits fibrosis and hypertrophy of non-infarcted myocardium and increases diastolic relaxation, raising the possibility that ACE2 activity may have some adverse effects on post-myocardial infarction heart [52]."}

{"project":"LitCovid-PubTator","denotations":[{"id":"746","span":{"begin":139,"end":143},"obj":"Gene"},{"id":"747","span":{"begin":308,"end":312},"obj":"Gene"},{"id":"842","span":{"begin":118,"end":121},"obj":"Gene"},{"id":"848","span":{"begin":20,"end":23},"obj":"Species"},{"id":"888","span":{"begin":114,"end":117},"obj":"Chemical"},{"id":"904","span":{"begin":33,"end":54},"obj":"Disease"},{"id":"905","span":{"begin":190,"end":198},"obj":"Disease"},{"id":"906","span":{"begin":203,"end":242},"obj":"Disease"},{"id":"907","span":{"begin":360,"end":387},"obj":"Disease"}],"attributes":[{"id":"A746","pred":"tao:has_database_id","subj":"746","obj":"Gene:302668"},{"id":"A747","pred":"tao:has_database_id","subj":"747","obj":"Gene:302668"},{"id":"A842","pred":"tao:has_database_id","subj":"842","obj":"Gene:100126231"},{"id":"A848","pred":"tao:has_database_id","subj":"848","obj":"Tax:10116"},{"id":"A904","pred":"tao:has_database_id","subj":"904","obj":"MESH:D009203"},{"id":"A905","pred":"tao:has_database_id","subj":"905","obj":"MESH:D005355"},{"id":"A906","pred":"tao:has_database_id","subj":"906","obj":"MESH:D006984"},{"id":"A907","pred":"tao:has_database_id","subj":"907","obj":"MESH:D009203"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Interestingly, in a rat model of myocardial infarction following coronary artery ligation, there is evidence that C16/MLN-4760 (a specific ACE2 inhibitor, see later) administration inhibits fibrosis and hypertrophy of non-infarcted myocardium and increases diastolic relaxation, raising the possibility that ACE2 activity may have some adverse effects on post-myocardial infarction heart [52]."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T131","span":{"begin":33,"end":54},"obj":"Disease"},{"id":"T132","span":{"begin":360,"end":381},"obj":"Disease"}],"attributes":[{"id":"A131","pred":"mondo_id","subj":"T131","obj":"http://purl.obolibrary.org/obo/MONDO_0005068"},{"id":"A132","pred":"mondo_id","subj":"T132","obj":"http://purl.obolibrary.org/obo/MONDO_0005068"}],"text":"Interestingly, in a rat model of myocardial infarction following coronary artery ligation, there is evidence that C16/MLN-4760 (a specific ACE2 inhibitor, see later) administration inhibits fibrosis and hypertrophy of non-infarcted myocardium and increases diastolic relaxation, raising the possibility that ACE2 activity may have some adverse effects on post-myocardial infarction heart [52]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T179","span":{"begin":18,"end":19},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T180","span":{"begin":74,"end":80},"obj":"http://purl.obolibrary.org/obo/UBERON_0001637"},{"id":"T181","span":{"begin":74,"end":80},"obj":"http://www.ebi.ac.uk/efo/EFO_0000814"},{"id":"T182","span":{"begin":114,"end":117},"obj":"http://purl.obolibrary.org/obo/CLO_0002096"},{"id":"T183","span":{"begin":128,"end":129},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T184","span":{"begin":232,"end":242},"obj":"http://purl.obolibrary.org/obo/UBERON_0002349"},{"id":"T185","span":{"begin":313,"end":321},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T186","span":{"begin":382,"end":387},"obj":"http://purl.obolibrary.org/obo/UBERON_0000948"},{"id":"T187","span":{"begin":382,"end":387},"obj":"http://purl.obolibrary.org/obo/UBERON_0007100"},{"id":"T188","span":{"begin":382,"end":387},"obj":"http://purl.obolibrary.org/obo/UBERON_0015228"},{"id":"T189","span":{"begin":382,"end":387},"obj":"http://www.ebi.ac.uk/efo/EFO_0000815"},{"id":"T190","span":{"begin":389,"end":391},"obj":"http://purl.obolibrary.org/obo/CLO_0001407"}],"text":"Interestingly, in a rat model of myocardial infarction following coronary artery ligation, there is evidence that C16/MLN-4760 (a specific ACE2 inhibitor, see later) administration inhibits fibrosis and hypertrophy of non-infarcted myocardium and increases diastolic relaxation, raising the possibility that ACE2 activity may have some adverse effects on post-myocardial infarction heart [52]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T107","span":{"begin":114,"end":117},"obj":"Chemical"},{"id":"T108","span":{"begin":139,"end":153},"obj":"Chemical"},{"id":"T109","span":{"begin":144,"end":153},"obj":"Chemical"}],"attributes":[{"id":"A107","pred":"chebi_id","subj":"T107","obj":"http://purl.obolibrary.org/obo/CHEBI_15756"},{"id":"A108","pred":"chebi_id","subj":"T108","obj":"http://purl.obolibrary.org/obo/CHEBI_147289"},{"id":"A109","pred":"chebi_id","subj":"T109","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"}],"text":"Interestingly, in a rat model of myocardial infarction following coronary artery ligation, there is evidence that C16/MLN-4760 (a specific ACE2 inhibitor, see later) administration inhibits fibrosis and hypertrophy of non-infarcted myocardium and increases diastolic relaxation, raising the possibility that ACE2 activity may have some adverse effects on post-myocardial infarction heart [52]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T83","span":{"begin":0,"end":393},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Interestingly, in a rat model of myocardial infarction following coronary artery ligation, there is evidence that C16/MLN-4760 (a specific ACE2 inhibitor, see later) administration inhibits fibrosis and hypertrophy of non-infarcted myocardium and increases diastolic relaxation, raising the possibility that ACE2 activity may have some adverse effects on post-myocardial infarction heart [52]."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T23","span":{"begin":33,"end":54},"obj":"Phenotype"},{"id":"T24","span":{"begin":360,"end":381},"obj":"Phenotype"}],"attributes":[{"id":"A23","pred":"hp_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/HP_0001658"},{"id":"A24","pred":"hp_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/HP_0001658"}],"text":"Interestingly, in a rat model of myocardial infarction following coronary artery ligation, there is evidence that C16/MLN-4760 (a specific ACE2 inhibitor, see later) administration inhibits fibrosis and hypertrophy of non-infarcted myocardium and increases diastolic relaxation, raising the possibility that ACE2 activity may have some adverse effects on post-myocardial infarction heart [52]."}

{"project":"2_test","denotations":[{"id":"32708755-20797602-20678704","span":{"begin":389,"end":391},"obj":"20797602"}],"text":"Interestingly, in a rat model of myocardial infarction following coronary artery ligation, there is evidence that C16/MLN-4760 (a specific ACE2 inhibitor, see later) administration inhibits fibrosis and hypertrophy of non-infarcted myocardium and increases diastolic relaxation, raising the possibility that ACE2 activity may have some adverse effects on post-myocardial infarction heart [52]."}